|
Effect of Sym004 on acquired resistance to cetuximab in colorectal cancer (CRC) in a novel mouse avatar model. |
| |
|
Travel, Accommodations, Expenses - Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Janssen-Cilag |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Deutsches Arztebatt; Elsevier; Springer |
Consulting or Advisory Role - Amgen; Apceth; AstraZeneca; Merck Serono; Roche Pharma AG |
Speakers' Bureau - Abbott Diagnostics; Falk Foundation; GSB Pharma; Lilly; MedCongress; Medical Council of India; Merck Serono; Pfizer; Roche Pharma AG; Siemens Healthcare Diagnostics |
| |
|
No Relationships to Disclose |